Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

被引：1

作者：

Dreyling, Martin ^{[1
]}

Panayiotidis, Panayiotis ^{[2
]}

Follows, George A. ^{[3
]}

Mollica, Luigina ^{[4
]}

Nagler, Arnon ^{[5
]}

Ozcan, Muhit ^{[6
]}

Santoro, Armando ^{[7
]}

Stevens, Don ^{[8
]}

Trevarthen, David ^{[9
]}

Hiemeyer, Florian ^{[10
]}

Liu, Li ^{[11
]}

Garcia-Vargas, Jose ^{[11
]}

Childs, Barrett H. ^{[11
]}

Zinzani, Pier Luigi ^{[12
]}

机构：

[1] Univ Hosp LMU, Dept Med 3, Munich, Germany

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[4] Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ, Canada

[5] Tel Aviv Univ, Chaim Sheba Med Ctr, Tel Hashomer, Israel

[6] Ankara Univ, Ankara, Turkey

[7] Humanitas Clin & Res Ctr, Rozzano, Italy

[8] Norton Canc Inst, Louisville, KY USA

[9] Comprehens Canc Care & Res Inst Colorado, Englewood, CO USA

[10] Bayer AG, Div Pharmaceut, Berlin, Germany

[11] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[12] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-121932

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1531

引用

页数：5

共 50 条

[41] DURABLE RESPONSES WITH IDELALISIB MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL)
Gyan, E.
Martin, P.
Armas, A.
Gopal, A. K.
Wagner-Johnston, N. D.
Abella-Dominicis, E.
Ye, W.
Philip, B.
Sorenson, B.
Walewski, J.
de Vos, S.
HAEMATOLOGICA, 2016, 101 : 757 - 758
[42] Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study
Noy, Ariela
de Vos, Sven
Thieblemont, Catherine
Martin, Peter
Flowers, Christopher
Morschhauser, Franck
Collins, Graham P.
Ma, Shuo
Coleman, Morton
Peles, Shachar
Smith, Stephen
Smith, Alina
Munneke, Brian
Dimery, Isaiah
Beaupre, Darrin
Chen, Robert W.
BLOOD, 2016, 128 (22)
[43] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study
Fowler, Nathan H.
Samaniego, Felipe
Jurczak, Wojciech
Lech-Maranda, Ewa
Ghosh, Nilanjan
Anz, Bertrand
Patten, Piers
Reeves, James A.
Leslie, Lori A.
Smolewski, Piotr
Chavez, Julio C.
Ghia, Paolo
Tarella, Corrado
Burke, John M.
Sharman, Jeff
Kolibaba, Kathryn
O'Connor, Owen A.
Cheah, Chan Y.
Miskin, Hari P.
Sportelli, Peter
Weiss, Michael S.
Zinzani, Pier Luigi
CANCER RESEARCH, 2019, 79 (13)
[44] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
Fowler, Nathan Hale
Samaniego, Felipe
Jurczak, Wojciech
Lech-Maranda, Ewa
Ghosh, Nilanjan
Patten, Piers
Reeves, James Andrew
Leslie, Lori Ann
Chavez, Julio C.
Ghia, Paolo
Tarella, Corrado
Burke, John M.
Sharman, Jeff Porter
Kolibaba, Kathryn
O'Connor, Owen A.
Cheah, Chan
Miskin, Hari P.
Sportelli, Peter
Weiss, Michael S.
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
Zinzani, Pier Luigi
Pellegrini, Cinzia
Derenzini, Enrico
Argnani, Lisa
Pileri, Stefano
HEMATOLOGICAL ONCOLOGY, 2013, 31 (04) : 223 - 224
[46] Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone
Cencini, Emanuele
Rocco, Melania
Ghio, Francesco
Simonetti, Federico
Cuccaro, Annarosa
De Marco, Federica
Consoli, Chiara
Bocchia, Monica
Fabbri, Alberto
EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (02) : 247 - 253
[47] Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Song, Yuqin
Song, Yongping
Liu, Lihong
Zhang, Mingzhi
Li, Zhiming
Ji, Chunyan
Xu, Wei
Liu, Ting
Xu, Bing
Wang, Xin
Gao, Sujun
Zhang, Huilai
Hu, Yu
Li, Yan
Cheng, Ying
Yang, Haiyan
Cao, Junning
Zhu, Zunmin
Hu, Jianda
Zhang, Wei
Jing, Hongmei
Ding, Kaiyang
Lu, Zhengguang
Zhang, Bin
Zhao, Renbin
Xu, Zhixin
Zhu, Jun
BLOOD, 2020, 136
[48] Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia
Wagner-Johnston, Nina D.
Schuster, Stephen J.
de Vos, Sven
Salles, Gilles A.
Jurczak, Wojciech
Rajakumaraswamy, Nishan
Xing, Guan
Gopal, Ajay K.
BLOOD, 2019, 134
[49] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Shibayama, Hirohiko
Choi, Ilseung
Hatake, Kiyohiko
Uchida, Toshiki
Nishikori, Momoko
Kinoshita, Tomohiro
Matsuno, Yoshihiro
Nishikawa, Tomoaki
Takahara, Satoko
Tobinai, Kensei
CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
[50] The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Opat, Stephen
Tedeschi, Alessandra
Linton, Kim
McKay, Pamela
Hu, Bei
Chan, Henry
Jin, Jie
Sobieraj-Teague, Magdalena
Zinzani, Pier Luigi
Coleman, Morton
Thieblemont, Catherine
Browett, Peter
Ke, Xiaoyan
Sun, Mingyuan
Marcus, Robert
Portell, Craig A.
Ardeshna, Kirit
Bijou, Fontanet
Walker, Patricia
Hawkes, Eliza A.
Mapp, Sally
Ho, Shir-Jing
Talaulikar, Dipti
Zhou, Ke-Shu
Co, Melannie
Li, Xiaotong
Zhou, Wenxiao
Cappellini, Massimo
Tankersley, Chris
Huang, Jane
Trotman, Judith
CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6323 - 6332

← 1 2 3 4 5 →